Sir,
We read with particular interest the article entitled ''Metabolic syndrome is not only a risk factor for cardiovascular diseases in systemic lupus erythematosus but is also associated with cumulative organ damage: a cross-sectional analysis of 311 patients'' by Demir et al., 1 which was recently published in Lupus. As with most previous studies on the prevalence of metabolic syndrome (MetS) in systemic lupus erythematosus (SLE), in which the prevalence varies greatly, it was found to be always greater than in nonlupus patients. This was the first Turkish study evaluating disease-specific factors and MetS, demonstrating that damage and disease duration were significantly associated with MetS and cardiovascular disease. However, using immunosuppressive drugs and hydroxychloroquine (HCQ) were not related to MetS. Nevertheless, HCQ had been a protective factor for cardiovascular disease, and cyclophosphamide, by contrast, a risk factor.
MetS, a bundle of cardiovascular risk factors, is highly prevalent and associated with increased rate of cardiovascular events and death. 2 Apart from these risk factors, MetS is closely correlated with inflammation. 3 Not only are they related to each other, but the inflammatory burst also precedes the MetS. 4 Then, chronic systemic inflammatory conditions, such obesity or types of rheumatic diseases, including SLE, are characterized by increased serum levels of circulating proinflammatory cytokines and activation of several inflammatory pathways involved in insulin resistance and atherogenesis. 5, 6 Systemic inflammation may provide a link between atherogenesis or metabolic diseases and inflammation in SLE. However, adipocytokine concentrations had not been strongly associated with Systemic Lupus Collaborating Clinics (SLICC) criteria or SLE Disease Activity Index (SLEDAI). 7 However, there is still no definitive answer on whether the disease-specific factors that reflect chronic inflammation, such as cumulated damage, may be involved in the development of MetS in SLE individuals. Thus, we evaluated the influence of SLICC criteria and other disease-specific factors in the presentation of MetS.
In order to evaluate these factors, we conducted a cross-sectional pilot study with 59 women with SLE according to the American College Rheumatology (ACR) criteria at the rheumatology outpatient clinic. Individuals with SLE had a higher prevalence of MetS (30.5%) than controls (20.5%), as shown previously. 8 Despite this higher prevalence, there was no significant association between the presence of SLE and whether individuals had MetS or not (p ¼ 0.117). Via a binary logistic regression, we assessed the chance of specific factors associated with SLE predicting the presence of MetS. No significant association was detected between MetS and any SLE specific factors (Table 1 ). This may have resulted from the lack of power in our study, determined by the small absolute number of patients with SLE fulfilling MetS criteria, not a real lack of association.
Although the Demir et al. paper corroborates the predominant data that individuals who develop MetS have increased cumulative organ damage whilst there is a protective effect of antimalarials, we have not reproduced these findings. The current evidence and the rational physiological explanation suggest that the lupus-MetS phenotype may be regulated by inflammation. 9 Nevertheless, it has been common to some studies; although these studies had been small and unconvincing concerning statistical power, they did not identify a single disease-specific factor predisposing to MetS. 10 Thus, the description of the mechanisms linking inflammation to metabolic diseases in SLE, the individualization of treatment plans, and larger prospective studies will help us to better identify lupus subjects at increased cardiovascular risk. 
